The Generic Pharmaceutical Association has called for policy makers to take steps to promote the development of competitive generic therapies and of biosimilars.
Even though rising production and use of generic pharmaceuticals is saving billions for the nation’s healthcare system, policy makers continue to slap the industry with policies it claims will limit product development and sales. A newreport from the Generic Pharmaceutical Association (GPhA) calculates that generic drugs saved $254 billion in 2014, and some $1.68 trillion over the past 10 years. Generics account for 88% of prescriptions (3.8 billion of total 4.3 billion prescriptions dispensed in the United States), according to analysis by the IMS Institute for Healthcare Informatics, but only 28% of drug spending. Policy makers thus should take steps to promote the development of competitive generic therapies and of biosimilars, says GPhA.
For the rest of this article, visit Pharmaceutical Technology.
FDA Approves AbbVie’s Rinvoq as First Oral JAK Inhibitor for Giant Cell Arteritis
April 30th 2025AbbVie secures FDA approval for Rinvoq as the first oral Janus kinase inhibitor indicated for giant cell arteritis, expanding its immunology portfolio and signaling strategic growth opportunities in underserved autoimmune markets.
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.